Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Circadian Therapeutics, a life sciences spinout of Oxford University, has been established to identify and bring to market pharmaceutical and diagnostic platforms for the effective management of physiological and pathological conditions through their ability to modify the body's circadian rhythms.

Alarm clock on a bed © Pollar SD - Shutterstock

Today, there are no safe, effective and fast-acting treatments that provide benefit to patients through modulation of circadian rhythms.

To address this, Circadian Therapeutics has identified drug candidates and is looking to study their effects on circadian rhythms in clinical trials. Simultaneously, the company is aiming to replace hospital-based, expensive diagnostics through the development of a home-based ambulatory electroencephalogram (EEG) device that will provide accurate and minimally intrusive measurement of brain function and circadian rhythms. The home-based monitoring of patients is vastly more cost effective and enables patient monitoring at scale, allowing for more precise and personalised medication. The combination of such products and technologies could be used for interventions across the health spectrum.

Read more

Similar stories

3,400 different medicines used globally to treat COVID-19

Coronavirus COVID-19 General Research

Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study.

Children and Adolescents’ Mental Health: One Year On

Coronavirus COVID-19 General Research

Parents and carers reported that behavioural, emotional and attentional difficulties in their children changed considerably throughout the past year, increasing in times of national lockdown and decreasing as restrictions eased and schools reopened, according to the latest Co-SPACE (COVID-19 Supporting Parents, Adolescents, and Children in Epidemics) study, led by experts at the University of Oxford.

Future-Proofing Mental Health

General Research

UK academics are calling for targets for mental health research in order to meet the healthcare challenges of the next decade. Published today in Journal of Mental Health, researchers set out four overarching goals that will speed up implementation of mental health research and give a clear direction for researchers and funders to focus their efforts when it comes to better understanding the treatment of mental health.

Promising malaria vaccine enters final stage of clinical testing in West Africa

Clinical Trials General Research

First vaccinations have now begun in Mali in a phase III trial of a malaria vaccine developed at the University of Oxford. Known as R21/Matrix-M, it recently showed efficacy of 77% over 12 months in a phase IIb trial, and it is hoped that this phase III trial will help to lead to licensure of this malaria vaccine by 2023.

Study reveals the three most important aspects of care for hip fractures

General Research

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.